Welcome to LookChem.com Sign In|Join Free

CAS

  • or

103942-79-6

Post Buying Request

103942-79-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

103942-79-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 103942-79-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,9,4 and 2 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 103942-79:
(8*1)+(7*0)+(6*3)+(5*9)+(4*4)+(3*2)+(2*7)+(1*9)=116
116 % 10 = 6
So 103942-79-6 is a valid CAS Registry Number.

103942-79-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 9-phenoxyphenazine-1-carboxylic acid

1.2 Other means of identification

Product number -
Other names 1-Phenazinecarboxylic acid,9-phenoxy

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:103942-79-6 SDS

103942-79-6Relevant articles and documents

Bis(phenazine-1-carboxamides): Structure-activity relationships for a new class of dual topoisomerase I/II directed anticancer drugs

Spicer, Julie A.,Gamage, Swarna A.,Rewcastle, Gordon W.,Finlay, Graeme J.,Bridewell, David J. A.,Baguley, Bruce C.,Denny, William A.

, p. 1350 - 1358 (2007/10/03)

Ring-substituted bis(phenazine-1-carboxamides), linked by a - (CH2)3NMe(CH2)3- chain, were prepared from the corresponding substituted phenazine-1-carboxylic acids by reaction of the intermediate imidazolides with bis(3-aminopropyl)methylamine. The compounds were evaluated for growth inhibitory activity in a panel of tumor cell lines, including P388 leukemia, Lewis lung carcinoma, and wild-type (JL(C)) and mutant (JL(A) and JL(D)) forms of human Jurkat leukemia. The latter mutant lines are resistant to topoisomerase (topo) II targeted agents because of lower levels of the enzyme. Analogues with small, lipophilic substituents (e.g., Me, Cl) at the 9-position were the most potent inhibitors, superior to the corresponding dimeric bis(acridine-4-carboxamides) (bis-DACA analogues). Several of the compounds were preferentially (up to 2-fold) more cytotoxic toward the mutant Jurkat lines than the wild-type. To test whether this selectivity was related to topoisomerase action, the most potent of the compounds (9-methyl) was evaluated in a cell-free system. It poisoned topo I at drug concentrations of 0.25 and 0.5 μM and inhibited the catalytic activity of both topo I and topo II at concentrations of 1 and 5 μM, respectively. Results from the NCI human tumor cell line panel showed the compounds had preferential activity toward colon tumor lines (on average 9.5-fold more active in the HT29 line than in the cell line panel as a whole). Several analogues produced significant growth delays in the relatively refractory subcutaneous colon 38 tumor model in vivo. In particular the 9-methyl compound was substantially more potent in this tumor model than the clinical dual topo I/II poison DACA (total dose 90 versus 400 mg/kg) with comparable activity. The bis(phenazine-1-carboxamides) are a new and interesting class of dual topo I/II-directed anticancer drugs.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 103942-79-6